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Background: The optimal duration of dual antiplatelet therapy after percutaneous coronary intervention (PCI)
remains uncertain. The objective of this study was to examine the association between duration of dual antiplatelet
therapy and re-hospitalization for acute coronary syndrome (ACS) in ACS patients who underwent PCI.
Methods: We identified 975 newly diagnosed ACS patients who underwent PCI between July, 2007 and June,
2009, at a medical center in Taiwan. Cox proportional hazard models were used to examine the association
between duration of dual antiplatelet therapy (9 months, 12 months and 15 months) and risks of re-hospitalization
for ACS.
Results: At a mean follow-up of 2.3 years, we found that use of clopidogrel for ≥ 12 months was associated with a
decreased risk of re-hospitalization for ACS (adjusted HR 0.59, 95% CI 0.36-0.95; p = 0.03). However, use of clopidogrel
for ≥ 15 months was not associated with a decreased risk of re-hospitalization for ACS (adjusted HR 0.57, 95% CI
0.29-1.13; p = 0.11). Similar results were found in patients who implanted drug-eluting stents (DES), for whom at
least 12 months of clopidogrel therapy is especially critical.
Conclusion: The benefit of ≥ 12 months of clopidogrel use in reducing the risk of re-hospitalization for ACS was
significant among ACS patients who underwent PCI and was especially critical for those who implanted DES.
Keywords: Acute coronary syndrome (ACS), Percutaneous coronary intervention (PCI), Clopidogrel, Dual
antiplatelet therapy, Drug eluting stent (DES)Background
The clinical benefits of clopidogrel in combination with
aspirin in acute coronary syndrome (ACS) patients under-
going percutaneous coronary intervention (PCI) have been
well demonstrated [1-4]. However, the optimal treatment
duration of dual antiplatelet therapy following PCI re-
mains uncertain. Findings from the PCI subpopulation of
the Clopidogrel in Unstable Angina to Prevent Recurrent
Events (PCI-CURE) [3] trial suggested that 3-12 months
duration of clopidogrel treatment after PCI significantly
reduced the risk of cardiovascular death, myocardial in-
farction and stroke. Nevertheless, other studies showed no* Correspondence: fyshsiao@ntu.edu.tw; csgau206@cde.org.tw
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The 2011 guideline issued by the American College of
Cardiology (ACC) and the American Heart Association
(AHA), however, has advocated an at least 12 months of
dual antiplatelet therapy following PCI and an extended
duration of treatment to at least 15 months and possibly
indefinitely for patients who received drug-eluting
stents (DES) [6]. The European Society of Cardiology
(ESC) Guidelines for the management of ACS in pa-
tients presenting without persistent ST-segment eleva-
tion and ST-elevation myocardial infarction (STEMI)
also suggest a 12-months of dual antiplatelet therapy
for these patients [7,8].
Several issues have been raised regarding the latest
guidelines [6]. First, the extended duration of 15 months
was suggested mainly due to the concern of late stent
thrombosis associated with DES. Although a slight increasetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Chen et al. BMC Cardiovascular Disorders 2014, 14:21 Page 2 of 8
http://www.biomedcentral.com/1471-2261/14/21in the risk of DES thrombosis after the first year has been
noted [9,10], there is no report to support the effectiveness
of a 15-months clopidogrel therapy. Secondly, prolonged
clopidogrel therapy could be costly and associated with
risks for major bleeding [11]. Thirdly, the recommenda-
tion of 12-months or even15-months of dual antiplatelet
therapy may not be generalizable to the non-US ACS
population, due to regional and health insurance plan lim-
itations. The conflict between the reimbursement policy
and latest clinical guidelines may further reflect urgent
needs for more evidence on the minimal necessary dur-
ation of dual antiplatelet therapy for ACS patients.
The objective of this study was to examine the associ-
ation between duration of dual antiplatelet therapy and
re-hospitalization for ACS in ACS patients who under-
went PCI. Specifically, we evaluated the clinical benefit




Patients included in this retrospective cohort study were
those who hospitalized for a newly-diagnosed ACS (Inter-
national Classification of Disease, Ninth Revision, Clinical
Diagnosis (ICD-9) CM codes: 410.xx, 411.xx, and 414.xx)
and who underwent PCI between July 1, 2007 and June 30,
2009 at a 2000-bed, university-affiliated, medical centre in
Taiwan. Eligible patients were those with no documented
ACS-related diagnoses or procedures before the index
ACS hospitalization. Patients who underwent both PCI
and coronary artery bypass graft (CABG), who received fi-
brinolytic agents during the index ACS hospitalization,
who received clopidogrel less than 7 days after discharge,
who lost to follow-up or for whom follow-up data were
not available were excluded.
Data collection
Baseline data were obtained from the hospital computer-
ized medical system and confirmed by reviewing patients’
medical records. For each patient, data during the index
ACS hospitalization were collected, including demographic
characteristics, family history, smoking history, body mass
index, biochemistry tests (including serum creatinine, total
cholesterol, triglyceride, fasting blood glucose, hemoglobin
A1c), comorbidities, left ventricular ejection fraction,
angiographic findings including extent of coronary artery
stenosis, stent type, diameter, length, and site of stent de-
ployment. Additional data collected were concomitant
medications used during the follow-up.
Clopidogrel use
All clopidogrel prescriptions were obtained from the
hospital electronic pharmacy prescription database. The
numbers of refills, doses, and pills dispensed of eachprescription after discharge were identified to calculate
the duration of clopidogrel use.
Study endpoint
The study endpoint was a re-hospitalization for ACS,
which was defined as a subsequent hospitalization with
a primary diagnosis of ACS (ICD-9 CM codes: 410.xx,
411.xx, 414.xx, and 996.72) after discharge from the
index ACS hospitalization. Medical records were reviewed
to further confirm the subsequent ACS hospitalization.
Study groups
In order to explore the association between clopidogrel
duration and re-hospitalization for ACS, we compared
the study endpoint in patients who received clopidogrel
for a certain duration after discharging from the index
hospitalization (categorized as “continuous users”) with
those who did not (categorized as “discontinuous users”).
Three predefined time points were used in our study:
9 months, 12 months and 15 months of clopidogrel use.
For example, in the “9-months analysis”, patients who
were event-free at 9 months were categorized into con-
tinuous users (received clopidogrel for ≥ 9 months) and
discontinuous users (received clopidogrel for < 9 months).
On categorization, a window of 30 days was allowed
for potential time lag between 2 prescriptions. Similar
algorithm were applied to the 12- and 15- months time
points.
Statistical analysis
Descriptive analyses of the differences between “continuous
users” and “discontinuous users” were conducted using χ2
and F values for categorical variables and t-tests for con-
tinuous variables.
Unadjusted event rates were compared between the
continuous and discontinuous clopidogrel users. Cox
proportional-hazard models were performed to estimate
the association between duration of clopidogrel use and
the risk of re-hospitalization for ACS. Patients who died
during the follow-up were censored. The univariate rela-
tions between baseline variables with ACS re-hospitalization
were first performed. We then performed multivariable
Cox regression models adjusted for variables with a sig-
nificance level of p-value < 0.15 identified in the univariate
analyses. Stepwise selections were further used to deter-
mine variables to retain in the models. The variable denot-
ing duration of clopidogrel use was retained in the model
irrespective of its statistical significance. Adjusted hazard
ratios (HRs) and 95% confidence intervals (CIs) were esti-
mated based on the stepwise selection. We performed
similar analyses in patients who implanted DES during the
index hospitalization. All analyses were performed using
the SAS statistical software, version 9.1 (SAS Institute,
Cary, North Carolina). This study was approved by the
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Results
Of the 2,641 patients newly hospitalized for ACS between
July 1, 2007 and June 30, 2009, we identified 1,382 patients
who underwent PCI. After applying the exclusion criteria,
we identified 975 patients as our initial study cohort
(Figure 1).
The 9-months analysis
The 9-months analysis included 744 patients who were
event-free at 9 months after the index hospitalization.
Patients in the continuous and discontinuous groups
were well balanced in terms of most baseline characteristics
(Tables 1 and 2). At a mean follow-up of 815 days
(27 months), the cumulative rates of ACS re-hospitalization
were 14.6% and 20.9% for continuous and discontinuousFigure 1 Study flowchart.clopidogrel users, respectively (Table 3). The clinical bene-
fit of use of clopidogrel for ≥ 9 months in reducing hazards
of ACS re-hospitalization was non-statistically significant
(adjusted HR 0.69, 95% CI 0.48-1.00; p = 0.05) (Table 3).
The 12-months analysis
At 12 months after the index hospitalization, 45% (317/699)
of patients were identified as continuous clopidogrel users.
Compared to discontinuous clopidogrel users, continuous
clopidogrel users were more likely to have a non-ST eleva-
tion myocardial infarction (NSTEMI) and DES implant-
ation at index hospitalization. Continuous clopidogrel
users had higher prevalence of hypertension, multi-vessel
disease, right coronary artery (RCA) stenosis, longer stent
length, and smaller stent diameter as well (Table 2).
Patients who received clopidogrel ≥ 12 months had a
lower crude incidence rate of re-hospitalization for ACS
(9.2%) compared to discontinuous group (13.9%). The





















Male 237 (81.2%) 350 (77.4%) 0.22 306 (80.1%) 248 (78.2%) 0.54 386 (78.9%) 131 (79.9%) 0.79
Age (years) 61.8 ± 12.0 63.1 ± 11.9 0.15 62.0 ± 12.3 63.3 ± 11.9 0.17 61.8 ± 11.7 64.2 ± 12.8 0.03*
BMI (kg/m2) 25.7 ± 3.8 25.5 ± 3.6 0.52 25.6 ± 3.7 25.6 ± 3.6 0.97 25.6 ± 3.7 25.7 ± 3.5 0.70
Current smokers 102 (35.1%) 128 (28.3%) 0.05 131 (34.3%) 90 (28.4%) 0.09 162 (33.1%) 43 (26.2%) 0.10
Previous smokers 56 (19.2%) 84 (18.6%) 0.82 72 (18.9%) 57(18.0 %) 0.77 91 (18.6%) 30 (18.3%) 0.93
Family history of CAD 61 (20.9%) 106 (23.5%) 0.41 78 (20.4%) 75 (23.7%) 0.30 105 (21.5%) 38 (23.2%) 0.65
Clcr (mL/min) 70.4 ± 25.4 68.8 ± 28.3 0.44 70.2 ± 26.1 68.6 ± 28.3 0.46 70.4 ± 26.2 66.9 ± 29.5 0.17
Cholesterol (mg/dL) 180.8 ± 39.4 182.4 ± 39.9 0.60 181.1 ± 37.2 182.8 ± 42.4 0.60 181.8 ± 38.8 181.9 ± 40.8 0.98
TG (mg/dL) 155.0 ± 98.4 146.2 ± 122 0.29 149.1 ± 95.0 150.0 ± 135 0.92 149.4 ± 118.8 149.5 ± 102 0.99
Glucose_AC (mg/dL) 113.2 ± 37.0 114.7 ± 34.9 0.63 113.1 ± 34.9 115.2 ± 37.8 0.52 114.7 ± 37.6 111.9 ± 33.2 0.46
HbA1c (%) 7.1 ± 2.2 7.0 ± 2.2 0.89 7.1 ± 2.2 6.7 ± 1.9 0.28 7.01 ± 2.0 6.48 ± 3.0 0.25
LVEF (%) 57.3 ± 11.4 55.9 ± 8.5 0.35 56.5 ± 10.6 55.9 ± 8.7 0.68 56.4 ± 10.0 55.1 ± 7.4 0.44
Comorbidities
Diabetes mellitus (DM) 89 (30.5%) 143 (31.6%) 0.74 117 (30.6%) 100 (31.6%) 0.79 152 (31.1%) 54 (32.9%) 0.66
Uncontrolled DM 32 (11.0%) 65 (14.4%) 0.18 48 (12.6%) 43 (13.6%) 0.70 65 (13.3%) 20 (12.2%) 0.72
Hyperlipidemia 130 (44.5%) 219 (48.5%) 0.29 175 (45.8%) 154 (48.6%) 0.47 229 (46.8%) 79 (48.2%) 0.77
Hypertension 188 (64.6%) 314 (69.6%) 0.15 241 (63.3%) 223 (70.6%) 0.04* 316 (64.9%) 119 (72.6%) 0.07
Heart failure 14 (4.8%) 21 (4.7%) 0.93 21 (5.5%) 12 (3.8%) 0.29 19 (3.9%) 10 (6.1%) 0.23
Arrhythmia 36 (12.3%) 70 (15.5%) 0.23 49 (12.9%) 49 (15.5%) 0.32 66 (13.5%) 27 (16.5%) 0.35
Cerebrovascular disease 18 (6.2) 21 (4.7) 0.37 21 (5.5%) 15 (4.8%) 0.66 26 (5.3) 9 (5.5) 1.00
Peripheral vascular disease 7 (2.4) 3 (0.7) 0.05 5 (1.3%) 3 (1.0%) 0.65 6 (1.2) 2 (1.2) 1.00
Chronic kidney disease 12 (4.1%) 26 (5.8%) 0.32 16 (4.2%) 20 (6.3%) 0.21 24 (4.9%) 9 (5.5%) 0.84
End-stage renal disease 5 (1.7%) 7 (1.6%) 1.00 6 (1.6%) 4 (1.3%) 0.73 6 (1.2%) 4 (2.4%) 0.28
GI ulcer/bleeding 32 (11.0%) 55 (12.2%) 0.62 44 (11.5%) 41 (12.9%) 0.57 52 (10.6%) 26 (15.9%) 0.07
Anemia 9 (3.1%) 15 (3.3%) 0.86 13 (3.4%) 9 (2.8%) 0.67 19 (3.9%) 3 (1.8%) 0.21
Co-medication
Aspirin 254 (87.0) 365 (80.8) 0.03* 334 (87.4) 229 (72.2) <.0001* 433 (88.6) 88 (53.7) <.0001*
ACEI/ ARB 188 (64.4) 310 (68.6) 0.23 239 (62.6) 220 (69.4) 0.06 313 (64.0) 110 (67.1) 0.48
β-blocker 187 (64.0) 319 (70.6) 0.06 233 (61.0) 221 (69.7) 0.02* 303 (62.0) 116 (70.7) 0.04*
Lipid-lowering agents 189 (64.7) 326 (72.1) 0.03* 251 (65.7) 223 (70.4) 0.19 319 (65.2) 118 (72.0) 0.11
Statin 177 (60.6) 313 (69.3) 0.02* 239 (62.6) 212 (66.9) 0.24 306 (62.6) 110 (67.1) 0.30
Warfarin 6 (2.1) 9 (2.0) 1.00 5 (1.3) 8 (2.5) 0.27 8 (1.6) 3 (1.8) 1.00
CCB 134 (45.9) 198 (43.8) 0.58 164 (42.9) 136 (42.9) 0.99 197 (40.3) 75 (45.7) 0.22
Nitrate 140 (48.0) 219 (48.5) 0.89 163 (42.7) 148 (46.7) 0.29 195 (39.9) 67 (40.9) 0.83
NSAID 28 (9.6) 40 (8.9) 0.73 33 (8.6) 21 (6.6) 0.32 29 (5.9) 14 (8.5) 0.24
COX-2 inhibitor 20 (6.9) 22 (4.9) 0.25 24 (6.3) 11 (3.5) 0.09 19 (3.9) 7 (4.3) 0.82
Digoxin 12 (4.1) 14 (3.1) 0.46 15 (3.9) 10 (3.2) 0.58 15 (3.1) 7 (4.3) 0.46
Diuretics 71 (24.3) 117 (25.9) 0.63 93 (24.4) 72 (22.7) 0.61 103 (21.1) 36 (22.0) 0.81
*p-value <0.05.
BMI = body mass index, CAD = coronary artery disease, Clcr = creatinine clearance, TG = triglyceride, Glucose_AC = fasting blood glucose,
HbA1C = glycosylated hemoglobin, LVEF = left ventricular ejection fraction, DM = diabetes mellitus, GI = gastro-intestinal, ACEI = angiotensin-converting enzyme
inhibitor, ARB = angiotensin II receptor blocker, CCB = calcium channel blocker, NSAID = nonsteroidal anti-inflammatory drug, COX = cyclooxygenase.
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STEMI 60 (20.6%) 124 (27.4%) 0.03* 95 (24.9%) 80 (25.2%) 0.91 127 (26.0%) 35 (21.3%) 0.23
NSTEMI 22 (7.5%) 76 (16.8%) <0.001* 41 (10.7%) 52 (16.4%) 0.03* 62 (12.7%) 26 (15.9%) 0.30
Non-elective PCI 43 (14.7%) 91 (20.1%) 0.06 69 (18.1%) 57 (18.0%) 0.98 89 (18.2%) 27 (16.5%) 0.61
IABP use 3 (1.0%) 8 (1.8%) 0.54 4 (1.1%) 7 (2.2%) 0.22 7 (1.4%) 3 (1.8%) 0.72
GP IIb IIIa inhibitors 7 (2.4%) 15 (3.3%) 0.47 12 (3.1%) 10 (3.2%) 0.99 15 (3.1%) 7 (4.3%) 0.19
Number of diseased
vessels
1.90 ± 0.85 2.03 ± 0.85 0.04* 1.91 ± 0.86 2.06 ± 0.85 0.02* 1.93 ± 0.86 2.04 ± 0.84 0.19
Multivessel PCI 93 (31.9%) 157 (34.7%) 0.42 115 (30.1%) 119 (37.5%) 0.04* 151 (30.9%) 68 (41.5%) 0.01*
Total occlusion 76 (26.0%) 153 (33.9%) 0.02* 106 (27.8%) 108 (34.1%) 0.07 142 (29.0%) 56 (34.2%) 0.22
Ostium lesion 18 (6.2%) 42 (9.3%) 0.13 24 (6.3%) 28 (8.8%) 0.20 29 (5.9%) 19 (11.6%) 0.01*
Bifurcation lesion 11 (3.8%) 25 (5.5%) 0.27 12 (3.1%) 18 (5.7%) 0.10 17 (3.5%) 10 (6.1%) 0.14
Location of stent
RCA 92 (31.5%) 162 (35.8%) 0.22 118 (30.9%) 124 (39.1%) 0.02* 161 (32.9%) 61 (37.2%) 0.32
LAD 177 (60.6%) 281 (62.2%) 0.67 238 (62.3%) 195 (61.5%) 0.83 303 (62.0%) 104 (63.4%) 0.74
LCX 78 (26.7%) 128 (28.3%) 0.63 99 (25.9%) 91 (28.7%) 0.41 131 (26.8%) 52 (31.7%) 0.22
LM 12 (4.1%) 27 (6.0%) 0.27 13 (3.4%) 19 (6.0%) 0.10 18 (3.7%) 12 (7.3%) 0.05*
Number of stents
1 stent 159 (54.5%) 219 (48.5%) 0.11 206 (53.9%) 147 (46.4%) 0.08 261 (53.4%) 67 (40.9%) 0.02*
≥ 2 stents 122 (41.8%) 222 (49.1%) 163 (42.7%) 162 (51.1%) 215 (44.0%) 91 (55.5%)
At least 1 DES 185 (63.4%) 369 (81.6%) <0.001* 252 (66.0%) 271 (85.5%) <0.001* 350 (71.6%) 140 (85.4%) <0.001*
Paclitaxel 53 (18.2) 103 (22.8) 0.13 72 (18.9) 75 (23.7) 0.12 91 (18.6) 44 (26.8) 0.02*
Sirolimus 76 (26.0) 134 (29.7) 0.28 103 (27.0) 94 (29.7) 0.43 139 (28.4) 49 (29.9) 0.72
Zotarolimus 49 (16.8) 105 (23.2) 0.03* 65 (17.0) 84 (26.5) 0.002* 95 (19.4) 43 (26.2) 0.07
Everolimus 12 (4.1) 45 (10.0) 0.003* 19 (5.0) 35 (11.0) 0.003* 35 (7.2) 14 (8.5) 0.56
EPC-capturing 11 (3.8) 13 (2.9) 0.50 15 (3.9) 7 (2.2) 0.20 17 (3.5) 4 (2.4) 0.62
Total stent length (mm) 39.6 ± 25.1 45.5 ± 30.2 0.01* 39.7 ± 24.9 46.9 ± 31.1 0.001* 41.4 ± 26.8 49.0 ± 32.7 0.01*
Min. stent diameter (mm) 3.04 ± 0.43 2.96 ± 0.47 0.03* 3.03 ± 0.44 2.95 ± 0.46 0.03* 3.0 ± 0.4 3.0 ± 0.5 0.27
*p-value <0.05.
STEMI = ST-elevation myocardial infarction, NSTEMI = non ST-elevation myocardial infarction, PCI = percutaneous coronary intervention, IABP = intra-aortic balloon
pumping, RCA = right coronary artery, LAD = left anterior descending, LCX left circumflex, LM = left main, EPC = endothelial progenitor cell.
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a mean follow-up of 2.2 years were statistically signifi-
cant in the multivariable Cox regression models (risk for
ACS re-hospitalization; adjusted HR 0.59, 95% CI 0.36-
0.95; p = 0.03) (Table 3).
The 15-months analysis
At 15 months after the index hospitalization, only 25%
(164/653) of patients continued their clopidogrel use for
more than 15 months. Compared to discontinuous
users, patients received ≥ 15 months of clopidogrel ther-
apy were older, had higher prevalence of multi-vessel
disease and multiple stents, longer stent length, and
were more likely to have a DES implantation duringindex hospitalization. Also, continuous users were more
likely to have ostial lesion or left main (LM) artery sten-
osis. A 15-months of clopidogrel therapy was not associ-
ated with a significant reduction in ACS re-hospitalization
(adjusted HR 0.57, 95% CI 0.29-1.13; p = 0.11) (Table 3).
DES-subgroup analysis
Among patients who underwent at least one DES im-
plantation, the risk of ACS re-hospitalization between
patients who received ≥ 9 (N = 369) and <9 months of
clopidogrel (N = 185) were not statistically different (ad-
justed HR 0.68; 95% CI 0.44-1.06; p = 0.09). In contrast,
those who received clopidogrel for ≥ 12 months (N = 271),
compared with those who discontinued within 12 months
Table 3 Adjusted hazards for ACS re-hospitalization by clopidogrel duration (9, 12, 15 months); full cohort
Clopidogrel use N Cases Crude
rate
Unadjusted hazard ratio p* Adjusted hazard ratio p*
HR (95% CI) HR (95% CI)
9 months
Discontinuous 292 61 20.9% 1.00 (Reference) 1.00 (Reference)
Continuous 452 66 14.6% 0.70 (0.49-0.99) 0.04 0.69 (0.48-1.00) * 0.05
12 months
Discontinuous 382 53 13.9% 1.00 (Reference) 1.00 (Reference)
Continuous 317 29 9.2% 0.66 (0.42-1.04) 0.07 0.59 (0.36-0.95) † 0.03
15 months
Discontinuous 489 45 9.2% 1.00 (Reference) 1.00 (Reference)
Continuous 164 13 7.9% 0.84 (0.45-1.56) 0.58 0.57 (0.29-1.13) ‡ 0.11
HR = hazard ratio, CI = confidence interval.
*Adjusted for comorbidities (hypertension, DM uncontrolled, myocardial infarction), use of aspirin, multivessel PCI, number of stents, at least 1 DES, total stent
length > 45 mm, minimum of stent diameter < 2.5 mm, ostium lesion, bifurcation lesion, LM lesion.
† Adjusted for comorbidities ( hypertension, DM uncontrolled, GI bleeding/ulcer, myocardial infarction) , use of aspirin, NSAID, multivessel PCI, number of stents,
at least 1 DES, total stent length > 45 mm, minimum of stent diameter < 2.5 mm, ostium lesion, bifurcation lesion, LM lesion.
‡ Adjusted for age, comorbidities (hypertension, DM uncontrolled, GI bleeding/ulcer, peripheral vascular disease, myocardial infarction), use of aspirin, NSAID,
multivessel PCI, number of stents, at least 1 DES, total stent length > 45 mm, minimum of stent diameter < 2.5 mm, ostium lesion, bifurcation lesion, LM lesion.
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hospitalization (adjusted HR 0.52; 95% CI 0.29-0.92;
p = 0.02). However, the aforementioned clinical benefit
was lost when clopidogrel therapy was extended for more
than 15 months (N = 140) (adjusted HR 0.76; 95% CI
0.37-1.56; p = 0.45) (Table 4).
Other risk factors of ACS re-hospitalization
Other factors associated with ACS re-hospitalization in
our multivariable Cox proportional models included
multi-vessel disease (adjusted HR 1.77, 95% CI 1.12-2.80;
p = 0.02), minimum of stent diameter < 2.5 mm (adjusted
HR 3.19, 95% CI 1.29-7.88; p = 0.01), use of NSAID
(adjusted HR 5.88, 95% CI 1.82-18.99; p = 0.003), and
uncontrolled diabetes mellitus (adjusted HR 1.88, 95%
CI 1.09-3.23; p = 0.02).
Discussion
The main finding of this study is that there is significant
benefit associated with ≥ 12 months of clopidogrel therapy
in reducing the risk of ACS re-hospitalization among pa-
tients who underwent PCI for ACS. Our study providesTable 4 Adjusted hazards for ACS re-hospitalization by clopid
DES-subgroup analysis Unadjusted hazard ratio
HR (95% CI)
Clopidogrel use for≥ 9 mo 0.71 (0.47-1.07)
Clopidogrel use for≥ 12 mo 0.58 (0.35-0.98)
Clopidogrel use for≥ 15 mo 0.91 (0.46-1.82)
*Adjusted for comorbidities (hypertension, DM uncontrolled, myocardial infarction), us
minimum of stent diameter < 2.5 mm, ostium lesion, bifurcation lesion, LM lesion.
† Adjusted for comorbidities (hypertension, DM uncontrolled, GI bleeding/ulcer, my
of stents, total stent length > 45 mm, minimum of stent diameter < 2.5 mm, ostium
‡ Adjusted for comorbidities (hypertension, DM uncontrolled, GI bleeding/ulcer, my
length > 45 mm, minimum of stent diameter < 2.5 mm, ostium lesion, bifurcation lefurther insights into clinical benefits of clopidogrel use be-
yond 12 months in this patient population. Nevertheless,
clopidogrel therapy ≥ 15 months is not associated with
significant clinical benefit in terms of reducing ACS re-
hospitalization. Similar results are found in the DES
population.
Our findings extend the current knowledge about the
duration of clopidogrel use in a “real-world” ACS popula-
tion. Conflicting data on the clinical benefits of continuous
use of dual antiplatelet therapy between 6 months to
12 months have been reported in prior studies [12-15].
Kimura and his colleague [12] showed that continuous use
of clopidogrel ≧ 6 months was not associated with a statis-
tically significant higher risk of MI or death compared
with continuous use of clopidogrel < 6 months (< 6 months
4.1% vs. ≧ 6 months 4.0%, p = 0.99). Park et al. [13] also
found that the hazard ratios of stent thrombosis (HR 1.38;
95% CI 0.17-11.21; p = 0.77) and death or MI (HR 1.16;
95% CI 0.56-2.42; p = 0.69) were comparable among
patients continuing and not continuing clopidogrel at
12 months. In contrast, the Clopidogrel for the Reduc-
tion of Events During Observation (CREDO) trial [14]ogrel duration (9, 12, 15 months); DES subgroup
p* Adjusted hazard ratio p*
HR (95% CI)
0.10 0.68 (0.44-1.06) * 0.09
0.04 0.52 (0.29-0.92) † 0.02
0.79 0.76 (0.37-1.56) ‡ 0.45
e of aspirin, NSAID, multivessel PCI, number of stents, total stent length > 45 mm,
ocardial infarction), use of aspirin, NSAID, cholesterol, multivessel PCI, number
lesion, bifurcation lesion, LM lesion.
ocardial infarction), use of NSAID, multivessel PCI, number of stents, total stent
sion, LM lesion.
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http://www.biomedcentral.com/1471-2261/14/21suggested that at 1 year, long-term clopidogrel use was
associated with a 26.9% relative reduction in the com-
bined risk of death, MI, or stroke (95% CI 3.9%-44.4%;
p = 0.02). Furthermore, an observational study done by
Eisenstein et al. [15] found that discontinued clopido-
grel before 12 months was associated with a higher risk
of MI or death (4.5% vs. 0%) in the DES but not in the
BMS group.
Along with several recent observational studies [16-18],
our findings support the latest ACC /AHA guideline [6]
that a at least 12-months of dual antiplatelet therapy fol-
lowing PCI would be beneficial to ACS patients. We
found that, at a mean follow-up of approximately 2 years,
9 months of clopidogrel therapy only provided a marginal
benefit in reducing the risk of ACS re-hospitalization
(adjusted HR 0.69, 95% CI 0.48-1.00; p = 0.05) while
12 months of clopidogrel use was associated with a 40%
reduction of the risk of ACS re-hospitalization (adjusted
HR 0.59, 95% CI 0.36-0.95; p = 0.03). The 12 months of
clopidogrel use is especially critical to the DES popula-
tion. Among DES patients, we found a larger reduction
in the hazard of ACS re-hospitalization (adjusted HR
0.52; 95% CI 0.29-0.92; p = 0.02) for patients received at
least 12 months of clopidogrel but not 9 months of clo-
pidogrel use.
Our study, however, does not support an extend dur-
ation of clopidogrel use to at least 15 months for pa-
tients who receive DES by the ACC /AHA guideline [6].
Our data shows that DES patients who received clopido-
grel for at least 15 months was not associated with a de-
creased hazard of ACS re-hospitalization (adjusted HR
0.76; 95% CI 0.37-1.56; p = 0.45). To date, our study may
be the first one to provide empirical evidence regarding
the clinical benefit of extended clopidogrel to 15 months
in ACS patients underwent PCI (especially DES). Given
the increased bleeding risk and inherent economic bur-
den with prolonged antiplatelet therapy [11,14], the most
clinical and economic efficient strategy is to assure a
12 months of clopidogrel to all ACS patients who undergo
PCI until we have more evidence.
There are inherent limitations with our retrospective
observational study design. As with any non-randomized
design, significant differences in comorbidities between
patients who continued clopidogrel or not could have
affected hazard estimations of ACS re-hospitalization.
However, our patients in the continuous and discontinu-
ous groups were well balanced in terms of most baseline
characteristics, including prevalence of peripheral vascu-
lar diseases. In addition, our hospital-based setting also
allowed us to adjust for a wide range of potential cardio-
vascular risk factors, including very detailed procedural
characteristics and information on other concomitant
medications (such as ACEI/ARBs, lipid-lowering agents,
and NSAID). Second, because of its retrospective nature,we do not know the reasons for clopidogrel discontinu-
ation. Thirdly, our findings may not be generalizable to
non-Asian populations. Previous study has indicated that
the cytochrome P450 (CYP) 2C19 poor metabolizers
may exhibit less antiplatelet activity when they were ex-
posed to the same clopidogrel regimen than other healthy
volunteers. The variation of prevalence of CYP2C19 poor
metabolizers in different populations (3-6% of Europeans
and Africans, and 13-23% of Asians) thus need to be taken
into account when interpreting our findings [19]. Fourthly,
we did not report risk of bleeding according to the dur-
ation of clopidogrel as it was not the main focus of our
study. Fifthly, we did not include newer antiplatelet agents
such as prasugrel and ticagrelor in our study as both of
them were not reimbursed by Taiwan’s NHI program dur-
ing our study period (prasugrel: currently not available;
ticagrelor (available since July, 2013)).
Despite these limitations, this study has several significant
methodological strengths. First, the medication utilization
data were based both on the hospital electronic pharmacy
prescription database and medical charts. Previous observa-
tional studies, however, relied on pharmacy claims [17,20]
and seldom captured clopidogrel use paid out-of-pocket.
Furthermore, because aspirin prescriptions are covered by
the NHI program, patients seldom obtain aspirin over the
counter. This allows us to capture the “dual” antiplatelet
therapy in our study cohort. For example, at 9 months of
follow-up, approximately 87% of the discontinuous users
and 80% of the continuous users concomitantly used as-
pirin. Another methodological strength with the hospital-
based data source is that we could include very detailed
procedural characteristics in our model to provide better
estimations of hazards of ACS re-hospitalization.
Conclusion
Our study provides new evidence on the minimal necessary
clopidogrel use in an ACS population. Together, our study
and findings of recently published studies support the latest
clinical guideline that a 12-months of clopidogrel therapy
conveys an important clinical benefit after PCI (especially
DES). Further studies are required to evaluate the clinical
benefits of clopidogrel use up to 15 months or more.
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